Back to search results

Understanding Muscle Changes in Myotonic Dystrophy

This study is looking at how myotonic dystrophy (DM), a type of muscular dystrophy, affects your muscles. Researchers want to see if a special type of MRI, called quantitative Magnetic Resonance Imaging (qMRI), can be used to measure changes in your muscles. They will measure your muscle volume and fat content at the beginning of the study. This information will help them understand how DM affects muscle structure and if qMRI can be a useful tool to track the disease and help in future drug development. You may be able to join if you are between 18 and 65 years old, have a diagnosis of DM1 or DM2, and experience muscle weakness or stiffness. The study aims to enroll 75 participants.

Study design
This is an observational study, meaning researchers will be watching and collecting information without giving any specific treatments. It plans to include 75 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07362875

Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

Recruiting
Not specifiedAges 18–65Observational
Wake Forest University Health Sciences
~75 participants
Updated 2026-01-23 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Contractile muscle volume (CMV, cm3)
Measured over Baseline
+1 more outcome measured

Conditions

Myotonic Dystrophy

Explore related trials

Myotonic Dystrophy

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Araya Puwanant, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Elizabeth (Gracie) G Hilber
[email protected]
336-716-4163
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 - 65 years
Diagnosis of DM1 or DM2 by clinical or genetic criteria. If DM1 or DM2 was diagnosed by clinical criteria, a first-degree relative must have genetic testing confirmation and sign a genetic consent form to release their genetic information
Clinically affected, as defined by muscle weakness or myotonia
Ambulate independently (a walker is not permitted)
Able to provide informed consent for participation in the study
Age 18 - 65 years old
Healthy as defined by no significant medical or neurological conditions
Able to provide informed consent for participation in the study

Exclusion

Cardiac pacemaker, defibrillator, metal implants, or other contraindications for MRI
Use of anabolic or catabolic agents within one year of entry
History of lumbar spine or leg surgery, lumbar radiculopathy, or peripheral neuropathy
BMI \> 35 because obesity compromises positioning on the MR scanner
Pregnancy
For muscle biopsy, history of bleeding disorders or on anticoagulation. Subjects taking nonsteroidal anti- inflammatory agents will be asked to discontinue these medications 7 days prior to muscle biopsy.

What this trial measures

  • Contractile muscle volume (CMV, cm3)Baseline

    Contractile muscle volume (CMV, cm3) of individual muscles and the total CMV within the thigh (anterior, medial, posterior) and calf (anterior, lateral, posterior) compartments

  • Muscle fat fraction (MFF, %)Baseline

    Muscle fat fraction (MFF, %) of individual muscles and the total CMV within the thigh (anterior, medial, posterior) and calf (anterior, lateral, posterior) compartments